Key result
High-dose Nifekalant (10-times clinical dose) induced torsades de pointes in 100% of atrioventricular block dogs, whereas the clinical dose did not induce the arrhythmia.
Why the study?
What are the electropharmacological and proarrhythmic effects of Nifekalant in canine models?
What are the electropharmacological and proarrhythmic effects of Nifekalant in canine models?
Nifekalant appears safe at clinical doses, but high doses can cause QT prolongation and torsades de pointes, particularly in the setting of bradycardia.
Answers are grounded in this paper and cite their sources.
Nifekalant shows dose-dependent effects in canine models; leaves open human proarrhythmic risk assessment.
Cardiovascular effects of Nifekalant were examined using halothane-anesthetized dogs, and its proarrhythmic potential was estimated with chronic complete atrioventricular block dogs. Nifekalant was intravenously administered to the halothane-anesthetized dogs in three doses of 0.03, 0.3, and 3 mg/kg/10 minutes with a pause of 20 minutes (n = 6). The low dose hardly affected any of the cardiovascular parameters. The middle dose, a clinically recommended antiarrhythmic dose, decreased the total peripheral resistance, increased the cardiac output, and prolonged the ventricular repolarization phase and effective refractory period. The high dose increased the left ventricular contraction, transiently decreased the mean blood pressure, and enhanced the atrioventricular conduction, besides potentiation of the changes induced by the middle dose. Increment in the repolarization phase by the high dose was greater than that in the refractoriness, leading to increase of ventricular electrical vulnerability. To the atrioventricular block animals, clinically relevant antiarrhythmic dose of 3 mg/kg p.o. of Nifekalant and its 10-times-higher dose were administered. The high dose prolonged QT interval leading to torsades de pointes in all animals (n = 5), which was not detected by the clinical dose (n = 5). These results suggest that antiarrhythmic dose of Nifekalant can be used safely; however, caution should be paid for patients complicating bradycardia and/or a risk of elevated plasma drug concentration.
No takes yet. Share an insight, caveat, or question.
Satoh et al. (2004) studied Animal model (dogs) (n=16). Nifekalant Hydrochloride vs. Clinical/low dose was evaluated on Torsades de pointes. High-dose Nifekalant (10-times clinical dose) induced torsades de pointes in 100% of atrioventricular block dogs, whereas the clinical dose did not induce the arrhythmia.
Synapse has enriched 10 related papers. Consider them for comparative context: